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effective targeting of the androgen receptor axis
in castration resistant prostate cancer (CRPC)
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Recent breakthrough therapies targeting androgen receptor signalling in castration resistant prostate cancer (CRPC)
involve multifunctional androgen receptor (AR) blockade and exhaustive androgen deprivation. Nevertheless,
limitations to an enduring effectiveness of new drugs are anticipated in resistance mechanisms occurring under
such treatments.
In this study we used CRPC cell models VCaP and LNCaP as well as AR-negative PC-3- and non-neoplastic epithelial
BPH-1-cells treated with 5, 10 or 25 μmol/L abiraterone hydrolyzed from abiraterone acetate (AA). The origin of
CYP17A1 up-regulation under AA treatment was investigated in CRPC cell models by qRT-PCR and western-blot
procedures.
AA treatments of AR positive CRPC cell models led to decreased expression of androgen regulated genes such as
PSA. In these cells diminished expression of androgen regulated genes was accompanied by an up-regulation of
CYP17A1 expression within short-term treatments. No such effects became evident in AR-negative PC-3 cells. AR
directed siRNA (siAR) used in VCaP cells significantly reduced mRNA expression and AR protein abundance. Such
interference with AR signalling in the absence of abiraterone acetate also caused a marked up-regulation of
CYP17A1 expression. Down-regulation of androgen regulated genes occurs in spite of an elevated expression of
CYP17A1, the very target enzyme for this drug. CYP17A1 up-regulation already takes place within such short
treatments with AA and does not require adaptation events over several cell cycles. CYP17A1 is also up-regulated
in the absence of AA when AR signalling is physically eliminated by siAR.
These results reveal an immediate counter-regulation of CYP17A1 expression whenever AR-signalling is inhibited
adequately but not a persisting adaptation yielding drug resistance.
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Prostate cancer is the second leading cause of cancer
death from the most frequently diagnosed malignancy in
males in the USA. As well in Europe prostate cancer
accounts for 9% of total cancer-related deaths. Standard
treatments for localized prostate cancer are radical sur-
gery, radiation therapy or active surveillance (Ferlay et al.
2007; Jemal et al. 2011). However conventional therapies
may fail as almost one-third of patients who undergo local* Correspondence: pthelen@gwdg.de
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in any medium, provided the original work is ptreatment will experience relapse and will receive andro-
gen deprivation therapy (Kantoff and Mohler 2013).
Within the last three years two alternative anti-
androgen strategies reached clinical application offering
new options in both pre- and post-chemotherapy setting
which emphasises the androgen receptor as sustained
therapy target in prostate cancer. Chemotherapy often
succeeds temporarily following therapy failure of con-
ventional hormone therapies. New drugs including abir-
aterone acetate (AA) and enzalutamide, effectively target
the androgen pathway to arrest aberrant signalling even
after multiple therapies. The mode of action of these
new compounds is either inhibition of androgen synthe-
sis at the CYP17A1 enzyme covering also adrenal andis an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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(AR) blockade antagonizes the AR function by directly
binding this transcription factor with high affinity.
Nevertheless, clinical success of these novel drugs is
not enduring in all cases. Recent phase 3 trials revealed
median time to PSA progression of about eight months
for both drugs and in sequential treatments of enzaluta-
mide and AA cross resistances have to be considered
(Schrader et al. 2013). Whilst the molecular mechanisms
for cross resistances occurring after sequential use of
androgen ablation and androgen receptor blockade are
still elusive, the alterations leading to individual therapy
resistance have been addressed in more detail. The
resistance mechanisms can be distinguished between
AR amplification/overexpression including alternative
AR splice variants (e.g. VCaP) and gain-of-function AR
mutations in the ligand binding domain (e.g. LNCaP)
associated with anti-androgen treatments notably fluta-
mide or bicalutamide (Knudsen and Penning 2010;
Waltering et al. 2012). Even for the second-generation
anti-androgen enzalutamide a ligand binding domain
mutation has been identified which converts the drug
from an AR antagonist to an AR agonist. However, this
mutation was identified in a mutagenesis screen in cell
models (Balbas et al. 2013).
Recent considerations of actual therapy resistance
include newly acquired mechanisms within the AR-axis
under the individual treatment and do not necessarily
require ultimate castration resistance as in AR-negative
cell models of prostate cancer (Feldman and Feldman
2001). In case of CYP17A1 inhibitor treatments an in-
creased expression of CYP17A1 thereafter was assumed
as a potential mechanism and dose escalation or
combined treatments with enzalutamide were suggested
to cope with this effect (Cai et al. 2011; Richards et al.
2012; Mostaghel et al. 2011). In the present study we
analyse the causation of CYP17A1 up-regulation and
discuss how this phenomenon qualifies for a therapy
resistance mechanism in distinct prostate and CRPC cell
models varying in AR status.
Methods
Culture cell lines and treatment
Human prostate cancer cell line VCaP was purchased
from ATCC, Wesel, Germany and kept in Phenol
red-free Gibco® DMEM lot # 1089200 (Life Technologies
GmbH, Darmstadt, Germany) supplemented with 2%
sodium pyruvate and 10% foetal calf serum (PAA, Cölbe,
Germany). The other cell lines LNCaP, PC-3 and BPH-1
from permanent local stocking were certified to proof
origin (Fuessel et al. 2013). Cells were incubated at 37 °C
and 5% CO2 in a humidified incubator. Cells and super-
natants were harvested for RNA and protein extraction
or used for ELISA assays. PSA release into cell culturemedia was measured with PSA-ELISA EIA-3719, (DRG
Instruments, Marburg, Germany). This study did not
require an approval from an ethics committee and the
local animal protection committee.
Abiraterone acetate (Janssen Cilag, Neuss, Germany)
was used for treatments in 5, 10 or 25 μmol/L concentra-
tion performed for 24 hours. To obtain the active drug
hydroxy-abiraterone (AA), abiraterone acetate was hydro-
lysed in 95% ethanol prior to use (Soifer et al. 2012).
siRNA transfection
The VCaP cells were transfected with siRNAs against the
androgen receptor (Riboxx Radebeul, Germany). To select
for best AR interference four different sequences were
used (Table 1). We chose the siRNA sequence ARex7
which had the highest down-regulation to 16% of regular
expression (Additional file 1: Figure S1). Before transfec-
tion for 24 h, 105 tumour cells were plated in six well
plates for 48 h in DMEM. The transfection medium
consists of 10 μl from a 20 μmol/l oligonucleotide stock
solution, 5 μl Oligofectamine reagent, 185 μl Opti-MEM
according to the manufacturer recommendation (Life
Technologies GmbH). Luciferase (LUC) siRNA was used
for control transfections (Eurogentec, Cologne, Germany).
mRNA-expression analysis
mRNA-expression of PSA, TMPRSS2-ERG, CYP17A1,
AKR1C3, AR and IGF-2 were analysed by qRT-PCR.
Total cellular RNA from cultured cells was extracted
with the Quick-RNA™MiniPrep (Zymo Research, Freiburg,
Germany). Total RNA integrity and quantity were assessed
on an Agilent Bioanalyzer 2100 with a RNA 6000 Nano
LabChipKit (Agilent Technologies, Waldbronn, Germany).
Reverse transcription of 500 ng total cellular (tc) RNA was
performed with random hexamer primers and an Omnis-
cript RT Kit (QIAGEN, Hilden, Germany). Expression ana-
lyses were processed on an iCycler iQ real time detection
system (BIORAD, Munich, Germany) with SsoFast
EvaGreen supermix. The 20 μl reaction from the kit was
supplemented with 2 μl cDNA, 0.6 μM gene-specific
primers (IBA, Göttingen, Germany). Primers were designed
by Primer 3 and PCR efficiency was assessed as previously
described (Stettner et al. 2007).
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Protein expression was measured by western blot analysis
with androgen receptor antibody Ab-2 (Cat. # RB-1358,
Lab Visions Corp. Fremond, CA, USA) and CYP17A1
antibody (Cat. 14447-1-AP, protein tech, Manchester,
United Kingdom) where α-tubulin was used as loading
control detected with a monoclonal anti-α-tubulin
(clone B-5-1-2, # T 5168, Sigma, St. Louis, MO, USA).
Cells were homogenized with Pierce® RIPA buffer
(Thermo Scientific, Rockford, IL, USA). Novex® precast
gels (Life Technologies, Darmstadt, Germany) were used
for electrophoresis followed by electro-transfer onto
Protran® nitrocellulose membranes (Whatman GmbH,
Dassel, Germany) from where protein-bound membrane
was hybridized with antibodies. For visualization, we used
Western Lightning® Plus-ECL (Perkin Elmer, Waltham,
MA, USA), rabbit secondary antibodies (P 0448 Dako,
Glostrup, Denmark) and ProteinSimple FluorChem E
(BioZym Hess. Oldendorf, Germany). For quantification of
band intensity Image J (http://imagej.nih.gov/ij/) was used.Statistical analyses
Statistical calculation, mean +/−SD and P values were
carried out with GraphPad Prism software version 5.0
using the unpaired nonparametric t test at 95% confidence
interval considered statistically significant (* = p < 0.05, ** =
p < 0.005 and *** = p < 0.0005).Results
Treatment of VCaP and LNCaP Cells with AA
CRPC cell line VCaP with overexpressed AR and LNCaP
with a gain-of-function AR mutation were treated
with 5, 10 or 25 μmol/L AA. In both cell lines PSA
mRNA expression decreased after treatment with AA
(Figure 1A + B). The same effect was found for
TMPRSS2-ERG expression in the VCaP cell line
(Figure 1C). According to the PSA mRNA expression
the PSA secretion also decreased (Figure 1D). In the
same experiments we looked for the expression profile
of CYP17A1 and AKR1C3. Concomitantly with the
detected decrease of androgen regulated genes PSA and
TMPRSS2-ERG, in both cell lines the CYP17A1 expres-
sion level significantly increased after treatment with
25 μmol/L AA (Figure 2A + B). In contrast, the down-
stream enzyme in testosterone biosynthesis, AKR1C3,
reveals decreased mRNA expression levels under such
treatments in VCaP but not in LNCaP cells (Figure 2C +D).
Counter-regulated CYP17A1 and AKR1C3 mRNA levels
were also found in the non-neoplastic cell line BPH-1
(Figure 3A + B) indicating an association of this phe-
nomenon with a non-mutated ligand binding domain of
the AR. In contrast to all other cell models the AR-
negative, malignant tumour cell line PC-3 treated with AAdoes not show any significant effects on CYP17A1 and
AKR1C3 expression (Figure 3C +D).
Targeting the AR in VCaP cells with siRNA elicits
CYP17A1-up-regulation in absence of AA
A siRNA against AR transcripts was used to elucidate
the relevance of AR signalling to the effects on
CYP17A1 and AKR1C3 expression in the absence of the
compound AA. AR directed siRNA significantly reduced
AR mRNA-expression and is also seen in western
blot analysis (Figure 4A), albeit high AR expression is
persistent in VCaP cells. However, this interference with
AR expression in the absence of AA also caused an
up-regulation of CYP17A1 expression in VCaP cells
(Figure 4B), but had only marginal effects on AKR1C3
expression (Figure 4C). Therefore, CYP17A1 up-regulation
is not dependent on AA presence and is based upon AR
impairment.
CYP17A1 enzyme inhibition and androgen receptor
expression under AA treatment
To elucidate by which function in AR signaling, receptor
status or androgen synthesis, androgen regulated genes
are affected, western blot analysis for the AR and
CYP17A1 were performed. In these experiments VCaP
cells were treated with 5 μmol/L AA. No significant
changes were detected on the AR protein level calculated
from western blot analyses (Figure 5A + C), whereas in the
same experiment CYP17A1 protein expression increased
markedly (Figure 5B + C). This experiment excludes a loss
of AR expression as an explanation for diminished
androgen receptor signaling and implies a full arrest of
CYP17A1-mediated androgen synthesis by AA even when
the enzyme was overexpressed.
Correlation of AA treatment effects on steroidogenesis
and IGF-2 expression
As the entire IGF-axis has significant influence on mecha-
nisms of castration resistance, IGF-2 is involved in path-
ways which can induce de novo steroidogenesis. Therefore,
we investigated the influence of AA on IGF-2 expression
in our different prostate cell models. Concomitant with
decreased expression of androgen regulated genes despite
CYP17A1 up-regulation, IGF-2 expression was also up-
regulated with increasing AA concentrations in VCaP
CRPC cells (Figure 6A). We also established aVCaP variant
reverted to androgen sensitivity termed VCaP CRPCrev.
These cells growing steadily under 1 nmol/L testosterone
showed a similar basic level of IGF-2 expression which was
not elevated with treatments of increasing AA concentra-
tions (Figure 6B). This indicates a marker function of IGF-2
for androgen deprivation. Under these conditions LNCaP
only showed an increased IGF-2 expression after treat-
ments of 25 μmol/L AA (Figure 6C). In contrast the
Figure 1 Expression profile of PSA and TMPRSS2-ERG: VCaP and LNCaP showing decreased PSA and TMPRSS2-ERG (VCaP) mRNA
expression after treatment with with 5, 10 or 25 μM AA (A-C). In addition treatment with 10 μM AA leads to a decreased PSA secretion in
VCaP (D); (* = p < 0.05, ** = p < 0.005 and *** = p < 0.0005).
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IGF-2 expression (Figure 6D) similar to VCAP CRPC cells
(Figure 6A). Interestingly, also AR negative malignant pros-
tate cancer cells (PC-3) exhibit an increased IGF-2 expres-
sion like LNCaP at higher AA concentration (Figure 6E). In
these PC-3 cells this increase of IGF-2 expression inFigure 2 Expression profile of CYP17A1 and AKR1C3: CYP17A1 expre
treatment with 25 μm AA (A + B). In addition AKR1C3 mRNA is decrease
**= p < 0.005 and ***= p < 0.0005).contrast to AR expressing cells is not associated with an
increase of CYP17A1 expression (Figure 3C).
Discussion
The huge progress made in the past few years to treat
CRPC with hormonal manipulation or AR blockade causedssion level is significantly increased in VCaP and LNCaP after
d in VCaP and increased in LNCaP cell line (C + D); (*= p < 0.05,
Figure 3 CYP17A1 and AKR1C3 expression in BPH-1 and PC3: increased CYP17A1 and decreased AKR1C3 mRNA in BPH-1 after
treatment with 25 μM AA (A + B). In PC-3 no significant effects after AA treatment in CYP17A1 and AKR1C3 mRNA expression could be seen
(C + D); (*= p < 0.05, **= p < 0.005 and ***= p < 0.0005).
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mised by resistance mechanisms acquired under these
novel treatments (Yuan et al. 2013). Therapy resistance
may result of ultimate castration resistance or other
undefined escape mechanisms. Such therapy resistances
developing under treatment and hence selective pressure
on tumour cells are distinguishable from mechanismsFigure 4 AR targeting siRNA in VCaP: siRNA against AR significantly red
in the absence of AA. No such effect is seen in AKR1C3 mRNA expression leresponsible for initial therapy failure in non-responding
patients. One obvious explanation for therapy induced
resistance is tumour growth of androgen independent
cell clones as evident in tumour cell models (Balbas et al.
2013; Sharma et al. 2010). Furthermore, therapy resistance
developed under AA treatments has been explained by
treatment-induced selection of tumour cells with elevateduced AR expression and an up-regulation of CYP17A1 expression
vels (A-D); (*= p < 0.05, **= p < 0.005 and ***= p < 0.0005).
Figure 5 Western Blot analysis of the AR and CYP17A1 after AA treatment with 5 μmol/L. In western blot analyses no significant changes
were detected on the AR protein level (A), whereas CYP17A1 protein expression increased markedly (B).
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by Cai et al. an increased mRNA becomes evident in VCaP
xenograft tumour bearing mice after long-term AA treat-
ments, whereas only one in four xenografts had increased
CYP17A1 expression in short term treatments with the
drug (Cai et al. 2011). From this phenomenon the authors
infer a de novo intratumoural steroid synthesis and a
mechanism contributing to AR reactivation and resistance
to CYP17A1 inhibitors.
In our short term in vitro experiments in VCaP cells,
however, we found an increased CYP17A1 expression with
increasing concentrations of AA within 24 hours. Despite
countering CYP17A1 expression androgen regulated genes
such as PSA or the fusion transcript TMPRSS2-ERG were
down-regulated with increasing AA concentrations, indi-
cating sufficiently suppressed androgen receptor signalling
in the presence of the drug. This confirms a still complete
inhibition by AA of basal and surplus CYP17A1 enzyme
activity under continuous treatment. To exclude an
alternative explanation for this finding we calculated AR
expression and CYP17A1 expression side-by-side from
western blot analyses (Figure 5). Hence, AR expression is
not affected by AA treatments with low concentrations of
5 μmol/L whereupon CYP17A1 is elevated then. This lead
to the conclusion that an inhibition of androgen signalling
in the presence of overexpressed CYP17A1 was not due to
altered AR expression.
Based on AR alterations there are two distinct expla-
nations for castration resistance and evolving therapyresistance. One is AR overexpression to retrieve trace
amounts of androgens and the other selection for ligand
binding domain mutations to utilize a variety of alterna-
tive ligands for activation (Balbas et al. 2013).
Although a direct interaction of AA with the AR and a
switch to an agonist of a mutated AR has been discussed
as mechanism for therapy resistance (Cronauer et al.
2013), our results can all be explained by an exclusive
AA effect on steroidogenesis and low affinity to AR. Ac-
tually, selection for a gain-of-function mutation in pros-
tate cancer cells is most conceivable when androgens
are scarce as under androgen deprivation and in the
presence of high-affinity AR ligand. A therapy resistance
based upon this principle may only arise under androgen
deprivation in combination with an anti-androgen with
demonstrable high affinity to the androgen receptor.
With an effective binding of a ligand, the incidence of a
gain-of-function mutation which turns an anti-androgen
into an androgen thusly granted prevalence for an
activated mutated AR no longer blocked by the anti-
androgen. Therefore, therapy resistance, especially a most
menacing anti-androgen withdrawal phenomenon is more
comprehensible for anti-androgen therapy than androgen
deprivation. In this study we showed that CYP17A1
up-regulation, the presumed resistance mechanism to AA
therapy is not restricted to androgen signalling in the
de facto presence of AA. When androgen signalling is
impaired by other means e.g. by RNA interference with
AR expression by specific siRNA (Figure 4) the same
Figure 6 Correlation of AA treatment on IGF-2 expression: IGF-2 is up-regulated in VCaP-CRPC, LNCaP, BPH-1 and PC3 after treatment
with 25 μm AA (A, C-E). In contrast IGF-2 expression was not elevated after treatments of increasing AA concentrations in VCaP-CRPCrev
(B); (*= p < 0.05, **= p < 0.005 and ***= p < 0.0005).
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hydroxyl-flutamide or bicalutamide treatment also showed
up-regulated CYP17A1 and down-regulated AKR1C3
expression (Kumagai et al. 2013), we demonstrated for AA
treatments (Figure 1). Therefore, CYP17A1 up-regulation
obviously is indicative for effective impairment of AR sig-
nalling in general not limited to AA treatments and may
represent a negative feedback loop (Auchus and Auchus
2012). Although all AA effects on AR positive cells VCaP,
LNCaP and BPH-1 appear to be attributed to an inhibitory
influence on steroidogenesis, our results from AR knock-
down experiments and AR negative PC-3 cells cannot
fully exclude the notion of AA binding the AR and partly
inhibiting AR-signalling. There are conflicting results from
previous studies which either excluded binding of AA to
AR or detected direct AA binding to the AR in vitro assaysdespite low affinity as compared with pure antiandrogens
(Handratta et al. 2005; Richards et al. 2012).
Our study revealed that a therapy resistance to AA treat-
ments is not satisfactorily explained by sole CYP17A1 up-
regulation. In addition to an up-regulation of CYP17A1
expression under AA treatments we also showed an in-
creased expression of IGF-2 in a concentration dependent
manner. Recent studies revealed new molecular pathways
by which IGF-2 confers androgen independent growth or
can ignite the de novo steroidogenesis engine and promote
molecular events associated with tumour progression
evading hormone therapy (Lubik et al. 2013; Comstock
and Knudsen 2013). IGF2 can activate the IGF1 receptor
or insulin receptor or hybrids of these two receptors to
contribute to prostate cancer progression to castration re-
sistance (Lubik et al. 2011). Further studies are warranted
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peptide hormones such as IGF-2 as response to androgen
deprivation and antiandrogen therapy and possible escape
mechanism to be targeted selectively in new therapy
attempts.
Conclusions
An up-regulation of CYP17A1 expression under AA treat-
ments is inconsistent with otherwise identified benefits in
CRPC therapy. The CYP17A1 up-regulation under AA is
not restricted to tumour cells but is elicited when AR sig-
naling is impaired. Therefore, this phenomenon represents
an immediate feedback loop upon AR impairment, rather
than an acquired, persisting drug resistance mechanism.
This means the search for the mechanisms of therapy
resistance in CRPC is not over. However, the recent antici-
pation of cross resistances after various anti-androgen
concepts suggests the last resort of therapy resistant
tumour cells is narrowed down to only few options.
Therefore, further research is warranted to target these
escape mechanisms unerringly, when even up-to-date
regimens begin to falter.
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